Semaglutide half-life & pharmacokinetics

Reported half-life

Approximately 165-184 hours (~7 days) plasma half-life through covalent fatty-acid binding to circulating serum albumin. Supports once-weekly subcutaneous dosing for the injectable formulations (Ozempic, Wegovy) and once-daily oral dosing with absorption-enhancing co-formulation (Rybelsus). The 7-day half-life is materially longer than liraglutide (~13 hours) and exenatide (~2.5 hours), reflecting the C18 fatty diacid modification specifically engineered for albumin retention.

The half-life and pharmacokinetic profile of Semaglutide reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (Ozempic, Wegovy — weekly licensed dosing)
• Oral tablet (Rybelsus — daily licensed dosing, co-formulated with SNAC absorption enhancer)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist; MHRA-licensed medicinal product for type-2 diabetes and chronic weight management.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Semaglutide acts as follows:

Semaglutide is a 31-amino-acid synthetic peptide structurally derived from native human GLP-1 with two engineered modifications that confer dramatic plasma half-life extension and protease resistance. The first modification is substitution of native alanine at position 8 with α-aminoisobutyric acid (Aib), an unnatural amino acid that blocks dipeptidyl peptidase-4 (DPP-4)-mediated cleavage of the N-terminal His-Ala bond — the principal degradation pathway of native GLP-1 (plasma half-life ~2 minutes). The second modification is covalent attachment of a C18 fatty diacid moiety to the ε-amino group of lysine 26 via a γ-glutamic acid and two short polyethylene glycol-like linkers (2xOEG). The fatty diacid chain binds non-covalently but with very high affinity to circulating serum albumin (~67 kDa), shielding the peptide from renal filtration and protease degradation and producing the ~7-day plasma half-life that supports once-weekly subcutaneous dosing.

See the full Semaglutide research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.